Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lusutrombopag for Thrombocytopenia in CLD (L-PLUS 2)
NCT02389621Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jun 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Thrombocytopenia comparing Lusutrombopag with Placebo (2 arms). Primary endpoint: Percentage of Participants Who Required No Platelet Transfusion Prior to the Primary Invasive Procedure and No Rescue Therapy For Bleeding up to 21 days. Started Jun 2015; status: completed.
02
Drugs
lusutrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT02389621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02389621.